• Resonance Health received a $732,851 refund from the Australian Taxation Office
• The refund is the net difference between the company's R&D tax incentive and income tax payable
• The cash refund will be added to Resonance Health's cash at bank

Resonance Health Limited (ASX: RHT) has announced that it has received a refund from the Australian Taxation Office (ATO) of $732,851. This amount is the net difference between the company's Research and Development (R&D) tax incentive refund for R&D performed in the FY2025 year totalling $832,959 and the total amount of income taxation payable by the company given its FY2025 financial performance, totalling $100,108. This cash refund amount will further add to the company's cash at bank, which will be reported in the March 2026 Appendix 4C & Quarterly Activities Report. Resonance Health is an Australian healthcare technology and services company that provides a range of regulatory-cleared Software-as-Medical Devices (SaMDs) for the assessment of human diseases and for use in clinical trials. The company has a strong focus on scientific rigour and quality, which has enabled it to achieve regulatory clearances in multiple jurisdictions and to carry ISO 13485 certification for the design and manufacture of medical devices.